In early April, Novartis drug Vanrafia won accelerated FDA approval as ... becoming the first FDA-approved treatment for C3 glomerulopathy, an ultra-rare kidney disease that can progress to ...

Novartis has claimed accelerated approval from the FDA for Vanrafia ... the treatment of rare kidney disease IgA nephropathy (IgAN). Vanrafia (atrasentan) is the first drug in the selective ...

Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental ...

If Regulus’ lead drug candidate, farabursen, gets regulatory approval ... Novartis – which has its U.S. headquarters in East Hanover – said the move will strengthen its lineup of kidney ...

an oligonucleotide targeting autosomal dominant polycystic kidney disease set to start phase III testing on a path to a potential accelerated approval. And now, there’s no need to, as Regulus found a ...

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

Vera Therapeutics faces a pivotal moment with Phase 3 data expected soon. Depending on the result, the stock may spike or ...

Merck's Welireg wins FDA approval for rare PPGL tumors; Q1 2025 sales reach $137M, marking a 62% year-over-year increase.

Novartis to acquire Regulus for $7/share upfront, a 108% premium to April 29 close and 274% over 60-day VWAP. The total deal could reach $1.7 billion if farabursen gains regulatory approval, with ...

FDA-approved drugs for IgA nephropathy ... is under development for IgAN and other rare kidney diseases. Following its acquisition of Chinook Therapeutics, Novartis is advancing atrasentan as ...

(Reuters) -Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental drug to treat a life-threatening kidney disease. Under the ...